Table 1.
CIN features during AML course and drugs used in preclinical and clinical studies.
| Features | Promising Agents 1 | |
|---|---|---|
| CK | [20,186,187] | PLK1 inhibitors [188]. In TP53 mutated: APR-246 [189] |
| Aneuploidy | [190,191] | PLK1 inhibitors [188]. In TP53 mutated: APR-246 [189] |
| TP53 | [192,193,194] | APR-246 with azacitidine (AZA) [195,196]. APR-246 alone [189], APR-246 combined with azacitidine [197,198]. |
| Abnormal 5q | [64,187,199,200] | PLK1 inhibitors [188]. In TP53 mutated: APR-246 [189] APR-246 with azacitidine [195,196]. APR-246 alone [189] |
| MYC abnormalities | [201,202] | Molibresib (GSK525762) [203,204] JQ1 combined with All-trans retinoic acid (ATRA) [205] Dihydroergotamine (DHE) [206] |
| Trisomy 8 | [118,119,120,121] | Molibresib (GSK525762) [203,204] JQ1 combined with All-trans retinoic acid (ATRA) [205] Dihydroergotamine (DHE) [206] |
| Telomere dysfunction | [136,144] | (hTERT) JQ1 combined with All-trans retinoic acid (ATRA) [205] Telomerase inhibitors [201,207]. |
| Dicentric chromosomes (DCs) | [150,208] | PLK1 inhibitors [188]. In TP53 mutated: APR-246 [189] APR-246 with azacitidine [195,196]. APR-246 alone [189] |
| Aurora Kinases | [100,101,102,103,209] | Small molecule inhibitors [210,211,212,213,214,215,216,217,218,219,220] |
| TET2 abnormalities | [173,221,222] | Decitabine [173]. Vitamin C combined with PARP inhibitor [223]. Ascorbate (Vitamin C) [224] |
| EZH2 abnormalities | [173,225] | Decitabine [173] |
1. Preclinical and clinical studies.